Skip to content

A randomized controlled trial of HAL for the efficacy and safety in hemiplegic patients with acute stroke

A randomized controlled trial of Wearable Cyborg HAL (Hybrid Assistive Limb) for the efficacy and safety in hemiplegic patients with acute stroke - A randomized controlled trial of Wearable Cyborg HAL for the efficacy and safety in hemiplegic patients with acute stroke

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs032200151
Enrollment
40
Registered
2020-10-14
Start date
2021-01-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke (cerebral infarction and cerebral hemorrhage)

Interventions

In the HAL group, gait treatment using HAL lower limb type (for both legs or single leg) is performed for 20 minutes once a day for a total of 9 times. In the control group, conventional gait training

Sponsors

Marushima Aiki
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who meet all of the following inclusion criteria and do not meet any of the exclusion criteria are eligible for this study enrollment. 1) Patients who can agree to the document by themselves. (However, if writing is difficult, set a writer.) 2) Patients aged 16 years or older. (If you are under 20 years old, in addition to the signature of the person himself/herself, signature by a parent or guardian is also need. 3) Patients within 7 to 21 days after onset. 4) Patients with Functional Ambulation Category (FAC) from 0 to 2. 5) Patients who can gait training using an all-in-one walker with a load-free function. 6) Patients who can be hospitalized for 4 weeks or more from the start date of the study. 7) Patients with FAC of 4 or more before onset. 8) The HAL group consists of patients who can wear the lower limb version of HAL. (Height is assumed to be 150 cm-190 cm, but the condition of use is not height, but for patients whose body size such as thigh length, lower leg length, waist width, etc. fits.)

Exclusion criteria

Exclusion criteria: 1) Patients who have difficulty performing voluntary limb movements according to instructions due to consciousness disorder or cognitive decline. 2) Patients who have difficulty in training joint exercises or wearing HAL due to complications such as heart disease and musculoskeletal system, which are problems during exercise. 3) Patients who cannot attach HAL bio-electrode due to skin diseases. 4) Patients who participated in other studies within 12 weeks of the start of this clinical study. 5) Patient who is judged to be medically unstable by the principal investigator or member doctors after comprehensively considering physical findings, blood test findings, etc.

Design outcomes

Primary

MeasureTime frame
Functional Ambulation Category (FAC)

Secondary

MeasureTime frame
Mini-Mental State Examination (MMSE) Brunnstrom Recovery Stage of lower limb Fugl-Meyer Assessment of lower limb Six-min walking distance (6MWD) Comfortable gait speed, step length, cadence Barthel Index (BI) Functional Independence Measure (FIM) Gait posture, motion analysis (muscle activity), evaluation using activity meter (amount of activity) Stroke Specific QOL (SS-QOL) Modified Rankin Scale (mRS) Disease occurrence status Test equipment failure

Contacts

Public ContactAiki Marushima

University of Tsukuba Hospital

aiki.marushima@md.tsukuba.ac.jp+81-29-853-3220

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026